Prospective randomized comparisons of ranitidine bismuth citrate (RBC) versus colloidal bismuth subcitrate (Denol)-based triple therapy for the treatment of H-pylori infection.

被引：0
|
作者：
Kung, NNS
Sung, JY
Yuen, WF
Li, TH
Ng, PW
Lai, WM
Leung, MF
机构：
[1] Chinese Univ Hong Kong, Hong Kong, Hong Kong
[2] United Christian Hosp, Dept Med, Hong Kong, Hong Kong
[3] United Christian Hosp, Dept Pathol, Hong Kong, Hong Kong
[4] United Christian Hosp, Dept Microbiol, Hong Kong, Hong Kong
来源：
GASTROENTEROLOGY | 1998年 / 114卷 / 04期
关键词：
D O I：
10.1016/S0016-5085(98)80774-9
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
G0780
引用
收藏
页码：A190 / A190
页数：1
相关论文
共 50 条
  • [1] A prospective randomized trial of one-week bismuth ranitidine citrate (RBC) triple therapies for H-pylori infection.
    Sung, JJY
    Chan, FKL
    Leung, WK
    Wu, JCY
    Suen, R
    Ling, TKW
    Lee, YT
    Cheng, AFB
    Chung, SCS
    GASTROENTEROLOGY, 1999, 116 (04) : A321 - A321
  • [2] Randomized comparison of ranitidine bismuth citrate (RBC)-based triple therapies for H-pylori
    Laine, L
    Estrada, R
    Trujillo, M
    Emami, S
    GUT, 1997, 41 : A103 - A104
  • [3] Randomized comparison of ranitidine bismuth citrate (RBC)-based triple therapies for H-pylori (HP).
    Laine, L
    Estrada, R
    Trujillo, M
    Emami, S
    GASTROENTEROLOGY, 1997, 112 (04) : A192 - A192
  • [4] One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy:: A prospective randomized controlled trial
    Kung, NNS
    Sung, JJY
    Yuen, NWF
    Li, TH
    Ng, PW
    Lai, WM
    Lui, YH
    Lam, KN
    Choi, CH
    Leung, MF
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1999, 94 (03): : 721 - 724
  • [5] Metronidazole resistance does not influence the efficacy of triple therapy with ranitidine bismuth citrate (RBC), clarithromycin (CLA) and metronidazole (MET) for H-pylori (Hp) infection.
    van der Wouden, EJ
    Thijs, JC
    van Zwet, AA
    Kooy, A
    Kleibeuker, JH
    GASTROENTEROLOGY, 1998, 114 (04) : A323 - A323
  • [6] Three months therapy with ranitidine bismuth citrate (RBC) reduces H-pylori-associated gastritis and density of H-pylori but does not cure the infection.
    Graham, DY
    Walsh, JH
    Schubert, TT
    Lanza, FL
    Peura, DA
    Peterson, W
    Riff, DS
    Yardley, J
    Ciociola, AA
    Kong, S
    Wood, D
    Webb, DD
    GASTROENTEROLOGY, 1996, 110 (04) : A122 - A122
  • [7] Prospective evaluation of ranitidine bismuth citrate-based triple therapy for the treatment of Helicobacter pylori infection
    Mönkemüller, KE
    Hirschowitz, BI
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1999, 13 (05) : 661 - 665
  • [8] The influence of metronidazole (MET) resistance on the efficacy of two triple therapy regimens with ranitidine bismuth citrate (RBC) for H-pylori (Hp) infection
    Van der Wouden, EJ
    Thijs, JC
    van Zwet, AA
    Kooy, A
    Kleibeuker, JH
    GUT, 1998, 43 : A86 - A86
  • [9] High H-pylori eradication rate with a one week triple regimen containing ranitidine bismuth citrate (RBC)
    Gudjonsson, H
    Bardhan, KD
    Hoie, O
    Kristensen, ES
    Schuetz, E
    KliebeFrisch, C
    Duggan, AE
    GUT, 1997, 41 : A99 - A99
  • [10] Ranitidine bismuth citrate (RBC) based triple therapy for 7 days is more effective than RBC plus clarithromycin for 14 days in dyspeptic patients with H-pylori infection
    Cestari, R
    Corti, G
    Formenti, A
    Galli, F
    Gatti, M
    Marotta, F
    Milesi, F
    Paterlini, A
    Piubello, W
    Ravelli, P
    Tonini, G
    Ubiali, P
    Valenghi, D
    Fina, P
    Olivieri, A
    Tosatto, R
    GUT, 1998, 43 : A83 - A84
12345